

INVERNESS MEDICAL INNOVATIONS INC

Form 8-K

May 02, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 2, 2008**

**INVERNESS MEDICAL INNOVATIONS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**1-16789**

(Commission File Number)

**04-3565120**

(IRS Employer  
Identification No.)

**51 Sawyer Road, Suite 200  
Waltham, Massachusetts 02453**

(Address of principal executive offices) (Zip Code)

**(781) 647-3900**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

EX-99.1 Consent of BDO Seidman, LLP

---

**Table of Contents**

**Item 8.01 Other Events.**

Inverness Medical Innovations, Inc. (the Company) is filing this Current Report on Form 8-K to include as an exhibit a consent of BDO Seidman, LLP, the Company's independent registered public accounting firm, to the incorporation by reference into the Company's Registration Statement on Form S-4/A (No. 333-149259) of its reports dated February 29, 2008 (except for the restatement discussed in Note 2(s), as to which is dated April 28, 2008) relating to the Company's consolidated financial statements and the effectiveness of the Company's internal control over financial reporting, which were included in the Company's Annual Report on Form 10-K, as amended, for the year ended December 31, 2007, filed with the Securities and Exchange Commission on April 29, 2008.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

**Exhibit No.    Description**

99.1            Consent of BDO Seidman, LLP.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INVERNESS MEDICAL  
INNOVATIONS, INC.**

By: /s/ Jay McNamara  
Jay McNamara  
Senior Counsel    Corporate & Finance

Date: May 2, 2008

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Consent of BDO Seidman, LLP.